Editorial Board

Professor Crespo-Facorro is a world-leading researcher in the area of early psychosis and has been leading one of the first early psychosis intervention program in Spain (PAFIP). Much of his work is aimed at prevention and early intervention of psychotic disorders. He has published over 280 peer-reviewed scientific articles (150 as senior author). His work was awarded with several national and international prizes, including the Banco Sabadell Foundation Biomedical Research Award. Current h index 54.

Senior Scientific at CSIC and Group Leader of CB/07/09/0034 at the Center for Networked Biomedical Research on Mental Health (CIBERSAM). Her research focuses on study of the neurobiological bases and the treatment of serious mental disorders such as schizophrenia, depression and the latter's comorbidity with Parkinson's disease. Much of her work is aimed at understanding the synaptic disturbances and brain circuits involved in mental disorders using pharmacological and genetic animal models to identify biomarkers and new targets for therapeutic action. She has designed new oligonucleotide-based therapeutic strategies for the treatment of depression and Parkinson's disease. Her research has been funded by the Brain and Behavior Foundation - NARSAD, Michael J Fox Foundation, Instituto de Salud Carlos III and Ministry of Economy and Competitiveness, among others. She has published over 60 papers in peer-reviewed journals, cited ~2.700 times (h = 24; Web of Science). Her work has been awarded with several national and international prizes, including the Pfizer Foundation Award in Basic Research category, the CSIC Award, and the joint recipient of the European College of Neuropsychopharmacology.

I'm a clinical academic affiliated to the Department of Psychiatry, University of Cambridge as Associate lecturer and clinically working as consultant psychiatrist to the local mental health services, where I lead the treatment resistant schizophrenia unit. Translating the schizophrenia research into novel clinical care interventions is paramount for me, so I also devote my time to the Comprehensive Research Network NIHR-CRN and the NIHR-HTA funding committee for large UK-based clinical trials. From the research point of view, I initially studied the molecular pathways that links schizophrenia with rest of the body (inflammation, ageing and metabolism) but more recently I moved into exploring factors associated with heterogenity in schizophrenia, particularly the neuroscience of negative symptoms and comorbid obsessive-compulsive disorder. My research has been funded by NARSAD, NIH (RO1), NIHR-BRC, NIHR-HTA and MRC-NIHR, among others.

Professor Ana González-Pinto is the Chair of the Psychiatry Department of the Hospital Universitario de Alava, Spain. She is also Assistant Professor of Psychiatry and Vice-Dean of the Faculty of Medicine of the Basque Country. She is the coordinator of the Bipolar Area of the CIBERSAM (Network Center of Research in Mental Health, Spain). In addition she is Chief of Research of Neurosciences in the BIOARABA Institute of Research, Basque Country. She has also been a member of the Educational Committee of the European College of Neuropsychopharmacology (ECNP). Dr González-Pinto has conducted her research on affective disorders and first psychotic episodes in Madrid, Bilbao, and Vitoria in Spain. She has published more than 200 articles in high impact factor journals. She has received research grant funding from the Horizon 2020, and other European Grants, and also National and Basque Government research grants. Her area of interest are bipolar, affective and psychotic disorders, focused especially in the first stages. Professor Ana González-Pinto is President of the National Society of Biological Psychiatry. She is part of the Board of Councils of the International Society of Bipolar Disorders. And has been President of the Vasco-Navarra Society of Psychiatry. She belongs to Several Editorial Boards of European Journals.

Graduated from Medical School Universidad Autónoma, Madrid, Spain, in 1992, became Adult Psychiatrist in December 1997 and Specialist in Child Psychiatry with a Diploma in the Institute of Psychiatry, Kings College, London in 1999. Doctor in Medicine, University Alcala, European Program.

Consultant in Psychiatry at the Hospital Gregorio Marañón in Madrid, at the Department of Child and Adolescent Psychiatry, since 2000. Dr Parellada holds an Assistant Professor Position at the School of Medicine, Universidad Complutense, Madrid and an Associate Visiting Professorship at the University of California in San Francisco, US. She has been conducting research and publishing in the area of first episodes of psychosis since 2003. She is an international trainer in the ADOS-2 since 2013.

Member of the CIBERSAM, Center for the National Research on Mental Health, through the Child and Adolescent Psychiatry Department, Instituto de Investigación Sanitaria Gregorio Marañón, at the HGUGM, in the last 16 years she has been the leader of the autism line of research of the group, to study the biological bases of autism spectrum disorders. This has gone in parallel with the set up and coordination of the first clinic in Spain for medical problems of ASD, AMITEA, where more than 4500 patients have been attended. She has published more than 200 papers in peer-review journals and has been P.I. of several peer-reviewed national and European public- and private-funded grants that study biological basis of autism and the overlap between autism and early-onset schizophrenia.

Leader of the Imaging of Mood- and Anxiety-Related Disorders (IMARD) group at IDIBAPS, Barcelona, and honorary researcher at the Institute of Psychiatry, Psychology & Neuroscience, King's College London, and the Karolinksa Institutet, Stockholm. Dr. Radua is psychiatrist and statistician specialized in mental health research using neuroimaging techniques, meta-analyses and umbrella reviews. One of his methods, Seed-based d Mappin (SDM), is one of the meta-analytic methods for voxel-based studies most used by the scientific community. He is one of the world's most influential scientific minds, according to Clarivate Analytics ranking (Highly Cited Researchers).

Miguel Ruiz Veguilla is a Psychiatrist who works as clinician as well as researcher at Hospital Universitario Virgen del Rocío (Sevilla) and Instituto de Biomedicina de Sevilla (IBiS). He has focused his research interests on the ethiopathogenesis of schizophrenia. Additionally, in the last years much of his work aimed at suicide prevetion.

Professor of Psychiatry at the University of Oviedo, Spain, and also member of the Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), of the Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), and of the Instituto Universitario de Neurociencias del Principado de Asturias (INEUROPA). She has been involved in research of bio-psycho-social aspects of suicidal behaviour and major mental disorders for over 25 years and she is co-author of several publications ranging from biological aspects to psycho-social correlates of those disorders. She has recently participated in different multicentre European research projects regarding the prevention and monitorization of suicidal behaviour in Europe (MONSUE Project) and the prevention of suicidality and other risk behaviours in young people, Saving and Empowering Young Lives in Europe - SEYLE Project and Working in Europe to Stop Truancy Among Youth - WE-STAY Project, funded by the EU 7th Framework Programme.

Professor of Psychiatry and Chair at the University of Barcelona and Head of the Department of Psychiatry and Psychology at the Hospital Clinic, where he also leads the Bipolar and Depressive Disorders Program in Barcelona, Catalonia, Spain. His unit is one of the worldwide leaders in clinical care, teaching and research on affective disorders. Dr. Vieta is also the current Scientific Director of the Spanish Research Network on Mental Health (CIBERSAM). He has received the Aristotle award (2005), the Mogens Schou award (2007), the Strategic Research award of the Spanish Society of Biological Psychiatry (2009), the Official College of Physicians award to Professional Excellence (2011), the Colvin Price on Outstanding Achievement in Mood Disorders Research by the Brain and Behaviour Research Foundation (2012), the Clinical Neuroscience Lilly award by the International College of Neuropsychopharmacology (CINP 2014), the Simon Bolivar Award (American Psychiatric Association 2017) and the Research Price of the World Federation of Societies of Biological Psychiatry (WFSBP, 2017). He has been named twice best psychiatrist in Spain (Monitor sanitario, El Español), honorary member of the Spanish Society of Biological Psychiatry, and Doctor Honoris Causa by the University of Valencia. He has authored more than 900 original articles, 450 book chapters and 43 books. His h index is 124 and has over 56.000 citations (Google Scholar), which makes him the most cited scientist worldwide in the field of bipolar disorder over the last 8 years and one of the world¿s most influential scientific minds, according to Clarivate Analytics ranking (Highly Cited). His papers have over 600.000 downloads. Furthermore, he is on the editorial board of many scientific journals and has served as invited professor at McLean Hospital and Harvard University and as neuroscience scientific advisor to the European Presidency.

Dr. Jurjen Luykx is a clinical scientist affiliated with Amsterdam University Medical Center and GGZ InGeest, Amsterdam, the Netherlands. He has a research background in psychiatric genetics and a broad interest in neurobiological, clinical, environmental, and societal issues related to psychiatry (including planetary mental health). Several days of the week he works as a clinical psychiatrist, consulting patients with difficult-to-treat psychosis, bipolar disorder and other types of severe mental illness. He enjoys conducting collaborative work in teams of researchers and clinicians, focusing on clinical trials, real-world studies and applied neuropsychiatric genetics (e.g. genetic epidemiology and cell type enrichment analysis). His overarching aim is to translate research findings to patients in the real world and convey such findings to medical students and residents, thus boosting precision psychiatry.